普洛药业(000739) - 2014 Q3 - 季度财报

Financial Performance - Operating revenue for the current period was CNY 1,129,299,913.55, a 1.07% increase year-on-year[7] - Net profit attributable to shareholders increased by 17.37% to CNY 51,342,890.97 for the current period[7] - Net profit attributable to shareholders after deducting non-recurring gains and losses increased by 14.72% to CNY 45,297,714.42[7] - Net cash flow from operating activities increased by 134.63% compared to the same period last year, primarily due to higher cash received from operating activities and lower cash paid[15] - The net profit for the year increased by 118.73% compared to the same period last year, mainly due to increased gross profit and investment income[15] Assets and Liabilities - Total assets increased by 8.22% to CNY 5,045,323,029.18 compared to the end of the previous year[7] - The balance of long-term prepaid expenses increased by 217.5% compared to the beginning of the period, mainly due to office renovation expenses incurred during the period[15] - The balance of development expenditures increased by 46.37% compared to the beginning of the period, primarily due to increased development investments[15] - The balance of construction in progress increased by 54.28% compared to the beginning of the period, mainly due to increased fixed asset investments[15] - The balance of cash and cash equivalents increased by 12.92 times compared to the same period last year, mainly due to significant increases in net cash from operating activities and new fundraising[15] - The balance of unappropriated profits increased by 45.59% compared to the beginning of the period, mainly due to investment income and increased gross profit[15] - The balance of short-term borrowings decreased by 33.00% compared to the beginning of the period, mainly due to repayment of part of the loans raised during the period[15] - The balance of accounts payable increased by 59.82% compared to the beginning of the period, mainly due to an increase in payment methods involving notes[15] - The balance of minority interests decreased by 35.70% compared to the beginning of the period, mainly due to the sale of subsidiaries reducing minority interests[15] Shareholder Information - Net assets attributable to shareholders increased by 37.39% to CNY 2,462,407,914.94 compared to the end of the previous year[7] - The total number of ordinary shareholders at the end of the reporting period was 57,111[11] - The largest shareholder, Hengdian Group Holdings, held 22.50% of the shares, totaling 258,097,452 shares[11] Earnings and Returns - Basic earnings per share decreased by 37.24% to CNY 0.0337 for the current period[7] - The weighted average return on equity was 2.21%, a decrease of 0.30% compared to the previous year[7]